Abstract
For the relatively nonimmunogenic B16-F10 murine melanoma, it has been found that genetically engineered expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) but not interleukin (IL)-2, IL-4, or interferon-gamma (IFN-gamma) resulted in a vaccine that could induce resistance to rechallenge. Because T cells from lymph nodes draining the sites of some progressive tumors can mediate tumor regression after in vitro activation, it seemed possible that even apparently nonimmunogenic melanoma cells might induce similar preeffector cells in the vaccine-draining lymph nodes (DLNs). C57BL/6 mice were vaccinated with B16-F10 cells that were either unmodified or genetically modified to produce IL-2, IL-4, GM-CSF, or IFN-gamma. DLNs were harvested 10 days after vaccination for adoptive immunotherapy (AIT). The DLN cells were activated with bryostatin 1 and ionomycin (B/I), expanded for 10 days in culture, and transferred to mice with 3-day pulmonary metastases. Pulmonary nodules were counted 14 days after AIT. Adoptive transfer of expanded DLN lymphocytes sensitized by inoculation of WT B16-F10, or IL-4, GM-CSF, or IFN-gamma expressing cells significantly reduced pulmonary metastases. Despite the spontaneous regression of ...Continue Reading
References
Aug 1, 1992·Surgical Oncology·T M TuttleH D Bear
Apr 1, 1991·The Journal of Experimental Medicine·M P ColomboG Parmiani
Nov 1, 1991·Science·P T GolumbekD M Pardoll
Oct 15, 1990·International Journal of Cancer. Journal International Du Cancer·R KellerP H van der Meide
Oct 1, 1990·The Journal of Experimental Medicine·B GansbacherE Gilboa
Feb 15, 1988·International Journal of Cancer. Journal International Du Cancer·M ZöllerA Ben-Ze'ev
Jan 1, 1988·Annual Review of Immunology·M Herlyn, H Koprowski
Aug 29, 1970·Nature·G R PettitH B Wood
Sep 1, 1981·The Journal of Experimental Medicine·E S DyeC D Mills
Apr 10, 1995·International Journal of Cancer. Journal International Du Cancer·I HaraA N Houghton
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·W SchmidtM L Birnstiel
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·G MaassT Schweighoffer
Aug 1, 1994·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·J C KraussS Shu
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G DranoffR C Mulligan
Apr 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·J D GeigerA E Chang
Aug 1, 1955·The Journal of Experimental Medicine·N A MITCHISON
Citations
Feb 10, 2009·Cancer Immunology, Immunotherapy : CII·Hanh K LeHarry Douglas Bear
Jun 19, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sheinei J SaleemDaniel H Conrad
Apr 24, 2015·International Journal of Molecular Sciences·Christine Kathryn ZoonHarry D Bear
Sep 25, 1999·Human Gene Therapy·S E BraunK Cornetta
Oct 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·H M HuB A Fox
Jun 25, 2002·Expert Opinion on Biological Therapy·Bela Bodey
Nov 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M SaioA B Frey
Aug 24, 2011·Journal of Translational Medicine·Natasja K van den EngelHauke Winter
Sep 26, 2001·Applied and Environmental Microbiology·S K DavidsonM G Haygood
Mar 24, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·D M Pardoll